AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1. (Currently Amended) A recombinant ~~replication-defective~~ chimpanzee adenoviral vector comprising a sequence of nucleotides derived from SEQ ID NO:1, wherein the vector has a functional deletion of the E1 gene in ~~which is at least partially deleted in E1 and devoid of E1 activity comprising the sequence of nucleotides as set forth in~~ SEQ ID NO: 1 and lacks E1 activity.

Claims 2-5. (Canceled)

Claim 6. (Currently Amended) The recombinant ~~replication defective~~ ChAd vector of claim 1 which comprises a deletion/disruption in the E1 nucleotide sequence in the region from bp 460 to bp 3542 of SEQ ID NO: 1.

Claim 7. (Canceled)

Claim 8. (Currently Amended) The recombinant ~~replication-defective~~ ChAd vector according to claim 6 wherein the vector further comprises a transgene encoding at least one tumor associated antigen (TAA) operatively linked to a promoter capable of directing expression of the transgene.

Claim 9-43. (Canceled)

Claim 44 (Currently Amended) An isolated host cell comprising the recombinant adenoviral vector of claim 1 ~~43~~.

Claim 45 (Currently Amended) A method for producing recombinant, ~~replication-defective~~ chimpanzee adenovirus particles comprising:

(a) transfecting a recombinant adenoviral vector of claim 1 into a population of cells; and

(b) harvesting the resulting recombinant, ~~replication-defective~~ adenovirus.

Claim 46 (Currently Amended) The recombinant ChAd vector of claim 1 ~~43~~, further comprising a transgene encoding ~~heterologous nucleic acid which encodes~~ at least one immunogen operatively linked to regulatory sequences which direct expression of said transgene ~~heterologous nucleic acid~~ in mammalian cells.

Claim 47 (Canceled)

Claim 48 (Currently Amended) The recombinant ChAd vector of claim 1 ~~43~~, wherein the vector further comprises at least a partial deletion of nucleotide sequences which encode the adenovirus E3 protein.

Claim 49 (Currently Amended) The recombinant ChAd vector of claim 1 [[43,]], wherein the vector is completely deleted in E1.

Claim 50 (Currently Amended) The isolated host cell of claim 44, wherein the host cell is a 293 cell or a ~~PER.C6™~~ cell as deposited with the ECACC under accession number 96022940 and wherein the cell propagates the recombinant adenoviral vector.

Claim 51 (New) The recombinant chimpanzee adenoviral vector according to claim 8 wherein the at least one TAA is selected from the group consisting of: HER2/Neu, CEA, EpCAM, PSA, PSMA, Telomerase, gp100, Melan-A/MART-1, Muc-1, NY-ESO-1, Survivin, Stromelysin 3, Tyrosinase, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, hKLP2, 5T4 AND VEGFR2.

Claim 52. (New) The recombinant chimpanzee adenoviral vector according to claim 46 wherein the transgene is derived from an infectious agent selected from the group consisting of: HIV, HBV, HCV, HPV, HSV1, HSV2, SARS COV, Plasmodium malariae, Ebola Virus, West Nile Virus, Dengue Virus, Influenza A, Influenza B, Mycobacterium tubercolosis, Cytomegalovirus, respiratory syncytial virus, and Leishmania major.